MARKET

TGTX

TGTX

Tg Therapeutics Inc
NASDAQ
53.89
-1.50
-2.71%
After Hours: 54.00 +0.11 +0.20% 19:30 09/11 EDT
OPEN
55.71
PREV CLOSE
55.39
HIGH
56.26
LOW
53.47
VOLUME
1.37M
TURNOVER
--
52 WEEK HIGH
59.30
52 WEEK LOW
26.76
MARKET CAP
8.25B
P/E (TTM)
19.63
1D
5D
1M
3M
1Y
5Y
1D
TG Therapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
Barchart · 3d ago
Weekly Report: what happened at TGTX last week (0831-0904)?
Weekly Report · 6d ago
Most shorted stocks on Wall Street
Seeking Alpha · 09/02 14:28
B. Riley Securities Remains a Buy on TG Therapeutics (TGTX)
TipRanks · 09/02 13:15
TG Therapeutics Price Target Maintained With a $78.00/Share by HC Wainwright & Co.
Dow Jones · 09/01 17:20
HC Wainwright & Co. Reiterates Buy on TG Therapeutics, Maintains $78 Price Target
Benzinga · 09/01 17:10
Analysts Offer Insights on Healthcare Companies: Adicet Bio (ACET) and TG Therapeutics (TGTX)
TipRanks · 09/01 16:00
H.C. Wainwright says Novartis success in RMS trials does not impact TG’s Briumvi
TipRanks · 09/01 15:35
More
About TGTX
TG Therapeutics, Inc. is a fully integrated, commercial stage biotechnology company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. Its products include Ublituximab IV (anti-CD20 mAb), Ublituximab IV Simplified Dosing Schedule, Ublituximab Subcutaneous (anti-CD20 mAb), and Azer-cel. It is engaged in late-stage clinical development of BRIUMVI. BRIUMVI is an anti-CD20 monoclonal antibody that can be administered to adults with relapsing forms of multiple sclerosis (RMS) in a one-hour infusion every 24 weeks, following the starting dose. It is used for treatment of adults with clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. The Company is also engaged in ULTIMATE I & II Trials Evaluating Single Agent Ublituximab in RMS. Its ENHANCE Phase 3b Trial is an ongoing, multi-center, open-label study designed to evaluate alternative dosing regimens for BRIUMVI in patients with RMS.

Webull offers TG Therapeutics Inc stock information, including NASDAQ: TGTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TGTX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading TGTX stock methods without spending real money on the virtual paper trading platform.